Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940496 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02940496: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02940496 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02940496, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate sorafenib.
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Ribavirin
- DRUG Elbasvir/Grazoprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02940496
The ClinicalTrials.gov registry entry for NCT02940496 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02940496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02940496 about?
NCT02940496 is a clinical study titled "Pembrolizumab (MK-3475) in Hepatocellular Carcinoma". This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate sorafenib.
What is the current status of trial NCT02940496?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2016-12-09. Estimated completion is 2023-08-09.
What interventions are being tested in trial NCT02940496?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Ribavirin (DRUG), Elbasvir/Grazoprevir (DRUG).
Who is sponsoring clinical trial NCT02940496?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.